Erasca, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan E. Lim
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3115 Merryfield Row San Diego CA United States of America 92121
- IPO Date
- Jul 16, 2021
- CIK
- 0001761918
- Website
- erasca.com
- Similar Companies
- Business
- Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers, which affect approximately 30% of human cancers; its pipeline includes naporafenib, a pan-RAF inhibitor for NRAS-mutant melanoma and RAS Q61X solid tumors studied in over 600 patients; ERAS-007, an oral ERK1/2 inhibitor for colorectal cancer, non-small cell lung cancer, and advanced gastrointestinal malignancies; ERAS-601, an oral SHP2 inhibitor for advanced solid tumors; ERAS-0015, a pan-RAS molecular glue evaluated in Phase 1 AURAS-1 trial for RAS-mutant solid tumors following FDA IND clearance in May 2025 and recent U.S. composition-of-matter patent issuance; ERAS-4001, a pan-KRAS inhibitor with FDA IND clearance for (K)RAS-mutant solid tumors; and ERAS-801, a CNS-penetrant EGFR inhibitor for recurrent glioblastoma multiforme, alongside a bispecific antibody targeting wildtype EGFR overexpression in head and neck squamous cell carcinoma and colorectal cancer. The company pursues three strategies: targeting upstream/downstream RAS/MAPK nodes, RAS directly, and resistance escape routes, with programs in Phase 1/2 trials including HERKULES-3 for ERAS-007 combinations, SEACRAFT-2 for naporafenib with Novartis' trametinib, and ongoing evaluations of monotherapy and combinations across multiple tumor types. Founded in 2018 and headquartered in San Diego, California, Erasca operates globally in clinical development, leveraging partnerships such as licensing agreements with Guangzhou Joyo Biotech for pan-RAS inhibitors, Medshine for pan-KRAS inhibitors, NiKang Therapeutics, Asana BioSciences, and Katmai Pharmaceuticals; recent developments encompass FDA IND approvals for ERAS-0015 and ERAS-4001 in 2025, preclinical data presentations at the AACR Annual Meeting in April 2025 highlighting superior potency, Q3 2025 business updates advancing the RAS franchise toward 2026 Phase 1 data readouts, and a cash position funding operations into late 2028.
Company News
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Frazier Life Sciences Management L.P. Has $457.55 Million Stock Position in Erasca, Inc. $ERAS
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
BlackRock Inc. Takes $387.54 Million Position in Erasca, Inc. $ERAS
Alger Mid Cap 40 ETF Q2 2026 Portfolio Review
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB
Bank of America Corp DE Raises Position in Erasca, Inc. $ERAS
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
ERASCA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERAS
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit
Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit